Protagenic Therapeutics, Inc.\new Subscription and Circulation Revenue (Deprecated 2018-01-31)
Protagenic Therapeutics, Inc.\new (PTIX) reported Subscription and Circulation Revenue (Deprecated 2018-01-31) of $2.50 million for the 3-month period ending 2011-09-30, per its 10-Q filed 2011-11-14.
Discontinued › Income Statement › Other Income
us-gaap:SubscriptionRevenue · last filed 2011-11-14
- Protagenic Therapeutics, Inc.\new subscription and circulation revenue (deprecated 2018-01-31) for the quarter ending 2011-09-30 was $2.50M, a 41.42% decline year-over-year.
- Protagenic Therapeutics, Inc.\new subscription and circulation revenue (deprecated 2018-01-31) for the quarter ending 2011-06-30 was $3.52M, a 29.49% decline year-over-year.
- Protagenic Therapeutics, Inc.\new subscription and circulation revenue (deprecated 2018-01-31) for the quarter ending 2010-09-30 was $4.26M.
- Protagenic Therapeutics, Inc.\new subscription and circulation revenue (deprecated 2018-01-31) for the quarter ending 2010-06-30 was $4.99M.
| Period end | Subscription and Circulation Revenue (Deprecated 2018-01-31) 3 month | Subscription and Circulation Revenue (Deprecated 2018-01-31) 6 month | Subscription and Circulation Revenue (Deprecated 2018-01-31) 9 month |
|---|---|---|---|
| 2011-09-30 | $2.50M 10-Q · filed 2011-11-14 | $6.01M derived: sum of 2 quarters · filed 2011-11-14 | $9.49M 10-Q · filed 2011-11-14 |
| 2011-06-30 | $3.52M 10-Q/A · filed 2011-09-07 | $7.00M 10-Q/A · filed 2011-09-07 | |
| 2010-09-30 | $4.26M 10-Q · filed 2011-11-14 | $9.25M derived: sum of 2 quarters · filed 2011-11-14 | $15.23M 10-Q · filed 2011-11-14 |
| 2010-06-30 | $4.99M 10-Q/A · filed 2011-09-07 | $10.97M 10-Q/A · filed 2011-09-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |